Online inquiry

IVTScrip™ mRNA-Anti-MSLN, MORAb-009(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12157MR)

This product GTTS-WQ12157MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets MSLN gene. The antibody can be applied in Pancreatic Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001177355.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10232
UniProt ID Q13421
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MSLN, MORAb-009(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12157MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8468MR IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HTI-1088
GTTS-WQ16009MR IVTScrip™ mRNA-Anti-ERBB2, ZW-25(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ZW-25
GTTS-WQ5687MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CDX-011 (DOX)
GTTS-WQ2327MR IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ALXN6000
GTTS-WQ4695MR IVTScrip™ mRNA-Anti-MAPT, BMS-986168(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-986168
GTTS-WQ1100MR IVTScrip™ mRNA-Anti-MAPT, ABBV-8E12(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABBV-8E12
GTTS-WQ1898MR IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AGEN2034
GTTS-WQ2881MR IVTScrip™ mRNA-Anti-CCR4, AMG-761(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG-761
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW